Pfizer Appoints Subha Madhavan as VP & Head of Clinical AI/ML, Early Clinical Development

(US and Canada) Pfizer, a global biopharmaceutical company, has appointed Subha Madhavan as Vice President & Head of Clinical AI/ML, Early Clinical Development.

Before joining Pfizer, Madhavan was AstraZeneca's Head of Data Science, Oncology R&D. She led cross-functional teams in early oncology, clinical development, R&D strategy, precision medicine, and competitive intelligence in bringing life-changing therapies to patients.

Madhavan is a dynamic and results-driven leader with a strong track record of excellence in organizations that operate in the nexus of science, technology, and business. She is a world-class leader in oncology R&D, precision medicine, digital health, data science & analytics, bioinformatics, product development, clinical informatics, and health IT. Her responsibilities have included initiating, designing, and executing several large national and international clinical research programs, including Cancer Moonshot, TCGA, CPTAC, and Human Cell Atlas. 

“I am very excited for the new opportunities in AI/ML that will help shape biopharma from small molecule design to precision medicine to global access in the future,” Madhavan said. “I am truly inspired by the potential role of such innovation in our relentless pursuit of scientific breakthroughs that will create a healthier world for everyone.”